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Cancer is a heterogeneous disease which has many subtypes that can be distinguished at 
molecular, histopathological, and clinical stage. Accurate diagnosis of the specific 
subtypes of cancer is vital to identify distinct disease states and opens up the possibility for 
effective personalized therapies that yield the greatest response. Many unsupervised 
machine learning techniques are applied to the genomic data of the tumor samples and the 
patient clusters are found to be of interest if they can be associated with a clinical outcome 
variable such as the survival of patients. In this thesis, we introduce two new clustering 
algorithms for cancer subtype identification, which fuses the information of gene 
expression and pathway database to group samples into biologically meaningful clusters. 
We call our first approach as R-PathCluster which is based on Restricted Boltzmann 
Machine. In this method, we used pathway markers as input dataset instead of gene 
expression data to identify unknown subtypes in Glioblastoma Multiforme (GBM). We 
developed SPACL model, sparse pathway based clustering for the identification of cancer 
subtypes in which multilayered deep belief network is used. In this model we used pathway 
data to extract the complex nonlinear relationships in identifying clusters. We assessed the 
performance of two models with several traditional clustering methods and found that our 
models out performed in clustering short term and long term survivals by lowest p-value 
in log rank test and Kaplan-Meier survival analysis. Our models provide solution to 
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1.1 Cancer Introduction 
Cancer is a complex genetic disease characterized by uncontrolled, uncoordinated, and 
undesirable growth of abnormal malignant cells [1]. Its development and progression are 
generally connected to a sequence of changes in the activity of cell cycle regulators like 
proteins and enzymes. They can originate from any parts of the body and has the ability 
to spread throughout the body. In a healthy human body, most body cells follow a regular 
path; they partition, proliferate, and programmatically die [2]. The cell division rate of 
normal cells varies at different phases of each person’s life. For instance, in younger 
person, healthy cells partition faster to enable him to grow properly, while in adult most 
of the cells divide to substitute aging or damaged cells in an adult.  Cancer cells, on the 
other hand, grow abnormally and divide for their whole lives, replicating into more and 
more harmful cells, which consequently form lumps or mass of tissue called tumors [3]. 
This unrestricted cellular growth eventually leads to a transformation of normal cells into 
tumor cells by infiltrating normal tissues and organs.  
 
The uncontrolled growth is caused by changes in DNA called genetic mutation. The DNA 
is a package of large number of individual genes, each of which contains a set of 
instructions telling the cell what functions to perform, as well as how to grow and divide. 





If it does not succeed, the cell dies. However, in cancerous cell, mutations in DNA repair 
genes can cause the cell to impair its normal function. As a result the cell does not die as 
it is supposed to but replicates with similar damaged DNA [4]. Although inherited 
damaged DNA play a major role in about 5 to 10 percent of all cancers [5], majority of 
the genetic mutations are non-hereditary.  
 
The mutations in DNA arise from multiple genetic and environmental factors. Genetic 
factors include faulty DNA copying introduced by DNA polymerases during cell 
division, Single Nucleotide Variants(SNV), small insertions and deletions (indels), larger 
copy number aberrations [6], gene expression changes, and epigenetic changes, including 
histone modifications and DNA methylation. Environmental factors include exposure to 
tobacco smoke, sunlight, etc. [7]. Exposure to Ultraviolet (UV) radiation and ionizing 
radiation (X-rays and atomic particles) damages DNA and transform normal cells into 
rapidly proliferating cancer cells. The ability of IR to cause leukemia cancer was 
significantly shown by the increased rates of leukemia among survivors of the nuclear 
bombs dropped in World War II [8][9]. Several studies have proved that long term 
exposure to sun damages DNA and cause melanoma, a type of skin cancer because of UV 
radiation[10]. 
 
Despite intensive efforts in research and treatment, cancer is still considered one of the 
leading causes of morbidity and mortality worldwide. According to the American Cancer 
Society, cancer is the second most common cause of death in the US, which accounts for 





According to North American Association of Central Cancer Registries  and National 
Center for Health Statistics, there were 1,735,350 new cases of cancer  and 609,640 
cancer deaths are projected to occur in 2018 in United States [12]. 
 
Early detection of tumors may increase patient’s survival chances. Therefore, it is 
important to develop new diagnostic techniques and medical treatments which helps 
people to fight against this insidious disease. A major obstacle to design effective cancer 
therapies is the accurate stratification of patients. For example, at the time of diagnosis, 
it is critical to distinguish which patients possess aggressive tumors and which of them 
progress slowly. Aggressive treatment methods practiced on the latter worsen the quality 
of the patient life.  
 
Cancer cells changes continuously while replicating because of aberrations in genes that 
regulate cell division. As the cancer advances over time, more genes will be aberrated 
leading to different types of daughter cancer cells. Although all cancer cells progress from 
single parent cell, the lump of cells that make up a cancer are not same, hence defined as 
heterogeneous. For example, when a breast cancer tumor is about one centimeter in size, 
millions of different cells that make up the lump are identified. Each cancer subtype has 
its own genetic identity, and gene expression pattern [13]. Thus two people with same 
age, height, weight, ethnicity, and similar medical histories, probably have two different 
breast cancer subtypes. It is therefore necessary to identify cancer subtypes in order to 
capture the characteristic essence of individual elements of this heterogeneous disease. 





combination therapy. For example, one subtype of breast cancer known as estrogen 
receptor (ER) positive respond well to hormone therapy, whereas the human epidermal 
growth factor receptor 2 (HER2) positive subtype respond well to chemotherapy but 
HER2 negative subtype does not respond to chemotherapy. [14]. Thus, identifying 
clinically relevant subtypes of cancer plays an important role in designing, developing 
and improving more personalized and effective prognosis/treatment.  
 
The genomic alterations in cancer cells have long been studied using low-throughput 
approaches, such as targeted gene sequencing, cytogenetic techniques [15], systematic 
mutagenesis [16], and genetic linkage analysis [17]. However, these traditional 
experimental approaches are tedious, time-consuming, and expensive [6]. Recent 
advancements in Next-Generation Sequencing (NGS) and high-throughput DNA 
sequencing techniques have revolutionized cancer genomics, and collaborative projects 
such as The Cancer Genome Atlas (TCGA) [18] and the International Cancer Genome 
Consortium (ICGC) [19] publicly released DNA sequences from thousands of tumors. 
These technologies along with emergence of hundreds of molecular markers have provided 
us with remarkable opportunity to study the molecular signatures of human cancers in a 
much more refined manner. In addition, large-scale cancer genomic studies have revealed 
wider genetic diversity in the same type of cancer as each subtype is characterized with 
unique behaviors in clinical and molecular profiles, such as survival rates, gene signature 
and copy number aberrations. Therefore, adequate methods are urgently needed to discover 
cancer subtypes to predict the biologic behavior and develop most effective therapeutic 






Cancer subtype discovery is to find out previously unknown subtypes. Several machine 
learning techniques have provided efficient solutions for cancer subtype discovery than 
those of histology based methods. In histopathology methods, cancer is detected by 
categorizing the image biopsy into cancerous or noncancerous by pathologists [20] and 
hence highly susceptible to human errors and bias. For identifying subtypes of 
adenocarcinoma, a type of lung cancer, the degree of agreement rate among independent 
pathologists was only 41% [21].   The fact that histology based methods are time 
consuming and not reliable [22] attracted machine learning approaches.  
 
Machine learning is a method of data analysis that allows the automation of model building 
and learning with given input data. As of today, there are a lot of machine learning 
algorithms available to choose for given problem. Furthermore, microarray data analysis 
methods are becoming cheaper and generating enormous amount of data. Therefore, a 
number of machine learning approaches have been explored [23][24]. Combining Gene 
expression data with clustering based approaches revolutionized cancer subtype 
identification and provides an important insight in analyzed gene expression data.  
 
In this thesis we proposed two novel pathway-based clustering methods based on 
unsupervised deep learning for discovering new cancer subtypes. Our methods 
incorporate prior biological knowledge of pathway data and simultaneously cluster 
samples into distinct groups. Integrating pathway database to clustering model itself helps 





informative clusters. These methods can more effectively identify clusters that are 
otherwise obscured by a large number of genes.  
 
In this thesis, we used Glioblastoma Multiforme cancer (GBM) dataset in order to evaluate 
our models clustering efficiency. GBM is the most common and lethal primary brain 
cancer, which accounts for about half of all malignant primary brain tumors [25]-[26]. 
GBM have historically been viewed as a single pathologic entity but mounting evidence 
suggests that distinct glioblastoma substantially differ at the molecular level from one 
patient to another. The studies in this thesis therefore aim to identify various GBM subtypes 
that can lead to targeted therapy.  
 
1.2 Problem Statement 
The problem that we have addressed in this work is to identify subtypes of Glioblastoma 
Multiforme (GBM) by using pathway data in order to biologically interpret the identified 
clusters for developing personalized medicine. Also to resolve the challenges caused by 







   The main contributions of this thesis are: 
• Proposed a new algorithm R-PathCluster, a pathway-based clustering method based on 
Restricted Boltzmann Machine for subtypes identification. 
• Proposed a novel model SPACL based on Deep Belief Networks approach for finding 
subtypes by extracting complex nonlinear relations in pathways. 
• Incorporating hierarchical representation of pathways. 
• Finding biological relationship for identified subtypes.  
1.4 Thesis Organization 
The thesis is organized as follows. This thesis comprises six chapters 
Chapter 1 introduces the thesis and states the problem definition.  
Chapter 2 provides a brief description of the GBM data and their subtypes.  
Chapter 3 describes related work in relation to our contributions.  
Chapter 4 discuss about the machine learning techniques used in this thesis. 
Chapter 5 introduces our proposed first novel approach R-PathCluster and its results and 
biological interpretation.  
Chapter 6 presents another novel approach SPACL, based on deep neural net and 
elaborates on empirical results of the experiments that we conducted as well as the 
comparisons with other methods and discussions. 








In this chapter we briefly introduce general information regarding GBM, its epidemiology, 
background, prevalence, incidence and its subtypes. 
 
2.1 Glioblastoma Multiforme (GBM) 
GBM is type of brain cancer which arise from brain supportive tissue called glial cells. 
These are highly aggressive tumors that rapidly infiltrate adjacent healthy brain tissue 
making very difficult to treat [27]. Although the etiology of glioblastoma has been 
thoroughly researched, immediate causes have not been found. In general, the causes of 
brain tumors are mostly unknown and hereditary factors can only be linked to 
approximately five percent of patients. Common factors that are thought to contribute to 
GBM development are genetic, environmental hazard. Due to the dismal prognosis, the 
World Health Organization (WHO) classifies GBM as a IV grade astrocytoma or high 
grade glioma (HGG) [28][25]. GBM is characterized by an extensive intratumoral 
heterogeneity which makes it extremely difficult to understand and treat, hence termed 
as ‘Multiforme’ [29][30]. The histopathological features of GBM include nuclear atypia, 
mitotic activity, cellular pleomorphism, microvascular proliferation, vascular thrombosis 
and necrosis [31][29]. This complexity, and putative cancer stem cell subpopulation 
combined with an incomplete atlas of epigenetic and genetic lesions, has contributed to 
make GBM complex disease [27]. These are most prevalent malignant tumors making up 





a subject’s death because of poor prognosis. It is estimated that 23,880 adults (13,720 
men and 10,160 women) and 3,560 children will be diagnosed with a primary brain tumor 
and central nervous system (CNS) tumor and 16,830 (9,490 men and 7,340 women) 
people will be estimated to die in the United States in 2018 [33]. Glioblastoma patients 
have a median overall survival time of around 14 months [34][35]. With intensive 
therapy, the median survival rate can be extended up to 14.6, 16.1 or 16.8 months 
according to Phase three clinical trials published in the New England Journal of Medicine 
[36][37]. The five-year survival rate which tells what percent of people live at least 5 
years after the tumor is found for primary malignant brain tumor is around 34% for men 
and 36% for women. Glioblastoma is a disease, which does not discriminate. It can occur 
at any age and to either gender but highest incidence rates can be seen in older males aged 
45-65 than females [38]. In children they develop in between 5 – 9 years of age. Only 3-
5% of Glioblastoma patients survive more than 3 years and are referred to as long-term 
survivors. Among all brain tumors, GBM show the greatest numbers of genetic 
abnormalities and considered as the highest-grade glioma with worst prognosis. The 
current standard treatment for this kind of cancer is the surgical resection followed by 




Glioblastoma itself can be categorized based on histopathology into conventional (93%), 
gliosarcoma (2%), or giant cell glioblastoma (5%) [40]. GBMs can be divided into de 
novo primary GBMs and secondary GBMs [41]. Primary GBM (pGBM) that develops 





from preexisting lower grade diffuse astrocytomas (grade II) or anaplastic astrocytoma 
(grade III) is less frequent. The pGBM is commonly seen in elderly patients and has a 
clinical history of less than 6 months while sGBM usually develops in younger patients 
[42]. Although both these subtypes don’t differ morphologically and clinically but can be 
distinguished based on genetic alterations and deregulations of molecular pathways[28].  
 
Based on progression and survival outcomes, The Cancer Genome Atlas (TCGA) and 
other groups have recently classified glioblastoma into gene expression-based subtypes. 
These include classical, pro-neural, neural, and mesenchymal [43]. Three subtypes were 
identified by array-based DNA methylation assay platforms in which one subtype formed 
a tight cluster with a highly characteristic DNA methylation profile "glioma CpG island 
methylator phenotype" or G-CIMP [44]. The G-CIMP subtype has high similarity for 
pro-neural subtype. The microRNA profiling study by Kim et al [45] identified five 
clinically and genetically distinct subclasses of glioblastoma based on neural precursor 
cell type. These include radial glia, oligoneuronal precursors, neuronal precursors, 
neuroepithelial/neural crest precursors and astrocyte precursors. Interestingly, when 
compared to the subclasses identified by Verhaak et al [43], the microRNA-based 
oligoneural, astrocyte, radial glial and subclasses were enriched in tumors from the 
proneural, mesenchymal and classical subtypes respectively. 
 
Accurate prediction of cancer subtypes can aid in directing patient’s therapies. Genomic 
techniques provide useful high-throughput tools for diagnosis and treatment of GBM 





allowed researchers to use unsupervised machine learning techniques to establish distinct 
tumor subtypes. Also early diagnosis underlies every therapeutic strategy against GBM by 









       
Rapid advancement in high throughput technologies enables the measurement of 
thousands of gene expression data simultaneously. Hence many studies are applying 
clustering techniques on high throughput multidimensional genomic data to identify 
cancer subtypes.  Hierarchical clustering algorithm is used on diffuse large B-cell 
lymphoma(DLBCL) cancer dataset to identify two subtypes that are distinguished from 
each other by the differential expression of hundreds of different genes, and these genes 
relate each subgroup to a separate stage of B-cell differentiation and activation [46]. As 
clustering algorithms like k-means, hierarchical were largely heuristic, model-based 
clustering methods were proposed to cluster gene expression data. In these methods, 
samples that are generated by multivariate normal distribution are clustered into best 
match distributions [47]. HMM-mix model was developed from model based clustering 
approach and identified cancer subtypes by analyzing comparative genomic hybridization 
(aCGH), which is data for DNA copy number alterations. 
 
Ensemble clustering techniques are used on gene expression data for stable and better 
performance than single clustering techniques. This technique provides a clustering 
ensemble by either using different clustering algorithms like k-means, hierarchical 
clustering, spectral clustering, etc. or using single clustering algorithm with different 





aggregate multiple clusterings on gene expression data of leukemia and melanoma 
cancers and identified 3 and 2 subtypes respectively [48]. Enhanced Maximum Block 
Improvement (eMBI), a new matrix factorization framework for biclustering identified 
five cancer subtypes in CRC and four subtypes in lung cancer [49].  
 
More recently, co-clustering or bi-clustering [50][51] methods are also used to identify 
cancer subtypes by analyzing gene expression data. Clustering only in the sample space 
may fail to discover the patterns that a set of samples exhibit similar gene expression 
behaviors only over a subset of genes. Co-clustering simultaneously performs clustering 
on both samples and genes [52]. These algorithms can produce sets of genes that are co-
regulated under sample subset. A network-assisted co-clustering method was developed 
to identify cancer subtypes (NCIS). In this method gene interaction network is combined 
with gene expression profiles in order to group genes and samples simultaneously into 
clusters which are biologically meaningful. This method divides samples into different 
clinical subtypes by assigning weights to genes depending on their connections in 
network [53]. Co-clustering ensemble is developed which is similar to clustering 
ensemble. This algorithm provides a framework by merging multiple base co-clustering 
results to generate a more stable and robust consensus co-clustering. Spectral co-
clustering ensemble was proposed, which uses bipartite graph partition to leverage 
multiple base co-clustering [54]. 
 
PathCluster, a software package was developed to use gene sets as input data to identify 





method also revealed unknown links between different annotation categories of clusters 
[55]. K-means algorithm was applied on Triple-Negative Breast Cancer (TNBC) gene 
expression data and identified seven subtypes and consensus clustering was employed to 
analyze the robustness of these subtypes [56]. Network based clustering approaches like 
‘Network-based Affinity Propagation’ (NetAP) model identified uterine endometrial 
carcinoma and adenocarcinoma cancer subtypes [57]. In this method, subtypes were 
identified by using affinity propagation clustering algorithm on gene similarity matrix of 
patients which was computed by constructing gene interaction network with genes and 
patient’s tumor profiles. 
 
Multimodal Deep Belief Network (DBN) was proposed to identify cancer subtypes in 
breast and ovarian cancers [58]. In this model, three Restricted Boltzmann Machines 
(RBMs) are employed, one each for multi-omics data, such as DNA methylation, miRNA 
expression, and gene expression. The hidden layers of all the three RBMs were merged 
by using common hidden layer at the top. This model also identified miRNAs and key 
genes that possess specific roles in the pathogenesis of cancer subtypes. Subtypes of 
human colorectal carcinoma was identified by Multimodal Deep Boltzmann Machines 
(DBM). This method incorporates both clinical data and gene expression on joint RBMs 
[59]. iCluster algorithm distinguish three distinct GBM tumor subtypes by using joint 
analysis of DNA methylation, gene expression data, and copy number variation [60]. 
 
As the subtypes of cancer differ in network or pathway level, identifying subtypes by 





we proposed two different pathway based clustering approaches to detect cancer 
subtypes. These two novel models have probabilistic neural network framework and use 








DEEP LEARNING TECNIQUES 
Deep learning, which is a branch of machine learning has more complicated algorithms 
that can model features with high-level abstraction from data. Currently, many deep 
learning methods have achieved success in computational biology. In this thesis we aimed 
at developing new approaches based on deep learning methods. Therefore, in this chapter 
we briefly introduce Restricted Boltzmann Machine (RBM) and Deep Belief Network on 
which R-PathCluster and novel methods are based on for clustering respectively. 
 
4.1 Restricted Boltzmann Machine 
 
Figure 4.1: Graphical depiction of an RBM 
Restricted Boltzmann Machine (RBM) is a probabilistic stochastic graphical model, 
which was initially introduced by Smolensky et al. in 1986, under the name Harmonium 





algorithm to train them [62]. RBM has visible (observed) and hidden (latent) layers. It 
is a model especially made to learn a probability distribution over the inputs. RBM can 
be understood as a Markov random field (MRF) with latent factors that explains the 
input visible data using binary latent variables. A node in the hidden layer is a 
transformation of the visible layer, and each node in the visible layer is a transformation 
of the nodes in the hidden layer. In RBM, each node has a probability and a state and 
both are used during training. A graphical depiction of an RBM is shown in Figure 4.1. 
Because of absence of intra connections with in the layers, the visible units are 
conditionally independent given the hidden units, and vice versa, so that both 
conditional distributions are easily tractable. The hidden units represent the posterior 
distribution of variables in the visible layer. 
 
Since the inter connections between the visible and latent hidden units form a 
bidirectional bipartite graph, a tractable learning algorithm is existed which trains a 
non-linear transformation function between these spaces. The non-linear 
transformation function is represented by the set of edges in the graph as well as two 
bias terms. The parameters of the transformation are computed by minimizing an 
energy function for the training set. If the energy increases, the probability that a 
generated visible value is represented by the data distribution decreases and vice versa. 
The energy function that is minimized in order to maximize the probability of the data 
is derived as: 











where v = (v1, v2 … vL) is the visible vector and h = (h1, h2 … hK) is the hidden 
representation, θ = {b, c, W} are model parameters in which  𝑐 ∈ ℝ𝐿 and 𝑏 ∈ ℝ𝐾 
are bias terms for visible and hidden layers respectively, W ∈ ℝ𝐿x𝐾 is a weight matrix 
that defines a potential symmetric connections between visible input variables and 
stochastic binary hidden variables. The joint probability distribution over vectors v and 
h can be defined from energy 𝐸(𝐯, 𝐡; θ) equation as: 







where Z(θ) is the normalizing constant or partition function that involves a sum of 
energies of all possible pairs of visible and hidden vectors. The probability of the visible 









From the above equations, the conditional distributions for visible and hidden vectors 








).  (6) 
Further simplified as: 
𝑝(ℎ𝑗 = 1|𝐯) = 𝑠𝑖𝑔 (∑𝑊𝑖𝑗𝑣𝑖 + 𝑏𝑗
𝑖





𝑝(𝑣𝑖 = 1|𝐡) = 𝑠𝑖𝑔 (∑𝑊𝑖𝑗ℎ𝑗 + 𝑐𝑖
𝑗
) , (8) 
where sig(x) = 1/(1+exp(-x)) is the logistic sigmoid function.  
 
The resulted conditional probability for a node is called its activation probability. 
Sampling the activation probabilities leads to states for the nodes. For each node the 
sampling function g(𝑥) is used to obtain the state of the node from its activation. For 
binary nodes, Bernoulli sampling is used to obtain states: 
g(x) = {




′ = 𝑔(ℎ𝑗), (10) 
𝑣𝑖
′ = 𝑔(𝑣𝑖). (11) 
For example, the state h𝑗 is set to 0 if the computed activation h𝑗 is lesser than a sample in 




RBMs are defined as energy based models. The probability of each configuration for a 
model is inversely proportional to the scalar energy. Hence, the higher the energy for a 
given state configuration, the lower the probability that network will be found in that state 
and vice versa. In other words, RBM maximize the probabilities of the input samples (v) 
or minimize the negative log likelihood with respect to parameters. The derivatives of the 







𝑙𝑜𝑔𝑝(𝐯) =  𝔼𝑃𝑑𝑎𝑡𝑎[𝑣𝑖ℎ𝑗]⏟        
𝐩𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐩𝐡𝐚𝐬𝐞





𝑙𝑜𝑔𝑝(𝐯) = 𝔼𝑃𝑑𝑎𝑡𝑎[ℎ𝑗] − 𝔼𝑃𝑚𝑜𝑑𝑒𝑙[ℎ𝑗],  (13) 
𝜕
𝜕𝑐𝑖
𝑙𝑜𝑔𝑝(𝐯) = 𝔼𝑃𝑑𝑎𝑡𝑎[𝑣𝑖] − 𝔼𝑃𝑚𝑜𝑑𝑒𝑙[𝑣?̂?],  (14) 
  
where 𝔼𝑃𝑑𝑎𝑡𝑎 [·] represents an expectation with respect to the data distribution 
𝑃𝑑𝑎𝑡𝑎(𝐡, 𝐯;  𝜃)  =  𝑃(𝐡|𝐯;  𝜃)𝑃𝑑𝑎𝑡𝑎(𝐯) , with 𝑃𝑑𝑎𝑡𝑎(𝐯)  = 
1
(N)
Σnδ(𝐯 − 𝐯n)   which 
represents the empirical distribution, and 𝔼𝑃𝑚𝑜𝑑𝑒𝑙[·]is an expectation with respect to the 
distribution defined by the model. 𝔼𝑃𝑑𝑎𝑡𝑎[·] can also be called as the data-dependent 
expectation, and 𝔼𝑃𝑚𝑜𝑑𝑒𝑙[·] as the model’s expectation.  
 
In RBM visible states are conditionally independent of hidden states and vice versa. The 
conditionally independent distributions (v|h) and 𝑝 (h|v) leads to Gibbs Sampling 
procedure, a Markov Chain Monte-Carlo (MCMC) algorithm. Gibbs sampling works by 
groups of two or more variables getting sampled and conditioned on all other group of 
variables. Thus, we sample (v|h) and 𝑝 (h|v) by alternating between 𝑣𝑖 ∼ p(𝑣𝑖|ℎ𝑗−1) and 
ℎ𝑗  ∼ p(ℎ𝑗|𝑣𝑖−1) and running a Markov chain to convergence. 
   
In equation (12), two parts of the gradients are generally referred as the positive and 
negative phases. It is easy to compute gradients of the positive phase as it is conditioned 
on the value of a training sample. The gradients of “negative phase” is difficult 





stationary state of the model and to get optimal parameters. Therefore, the approximation 
method called contrastive divergence (CD) algorithm was proposed in learning procedure 
in order to efficiently perform gradient descent. The CD algorithm tries to fix the 
parameters so that the probability distribution represented by the network corresponds to 
the training data and so that the arrangement expresses the relations between input 
features well. After learning, the RBM provides a finite representation of the 
observation’s distribution. 
 
4.1.2 Contrastive Divergence 
The CD algorithm is based on Gibbs sampling process, but does two specific 
optimizations. First, instead of starting at a random state of the visible units, it starts at 
the state of a training vector. Moreover, instead of waiting for the convergence of the 
Markov chain by taking infinite steps of Gibbs Sampling, it simply takes a limited number 
of steps (usually just one step) of Gibbs Sampling to approximate it. Figure 4.2 illustrate 
the Gibbs sampling step. The general idea behind CD is that even just a few steps of the 
Markov chain will provide a direction for the gradient in the state space for the Markov 
chain, and provide the training algorithm with the appropriate correction to the gradient. 
The CD algorithm can be done with a certain number 𝐾 of steps of Gibbs sampling (called 
CD-K), typically one full step of Gibbs sampling. Empirical results show that CD 
algorithm with one full step of Gibbs sampling is an effective and efficient learning 
algorithm. This has the advantage of not requiring to perform alternating Gibbs Sampling 
for many iterations. Overall, these improvements are making CD a very fast algorithm. 





equivalent to minimizing the Kullback-Leibler (KL) divergence between the data 




































































  (17) 
Notice that ?̂? in these equations indicates the reconstructed visible units sampled from 
the mth step of Gibbs Sampling.  
 
The CD-1 learning step for one sample can be summarized as follows:  
• Initialize the visible units to a training sample 𝐯0. 
• Compute the probabilities of the hidden units(𝐡0) and sample a hidden activation 
vector from 𝑃(𝐡|𝐯0).  
• Calculate the outer product of 𝐯0 and 𝐡0 and call this the positive gradient.  
• Compute the probabilities of the visible units (𝐯1) from 𝑃(𝐯|𝐡0). and sample a 
reconstruction (𝐯1) of the visible units.  
• Resample the hidden activations 𝐡1 based on𝐯1. (Gibbs sampling step).  
• Calculate the outer product of 𝐯1 and 𝐡1 and call this the negative gradient. 
• Update the weight matrix W based on the positive and negative gradients. 
 















RBM Update (v, W, b, c) 
v is a sample from training distribution 
W is the weight matrix 
b is bias vector for input units 
c is bias vector for hidden units 
η is learning rate for stochastic gradient descent in contrastive 
divergence 
repeat {over the training dataset} 
set v0 = v 
compute the posterior Q = (P (h| v0)) 
Sample h0 from Q 
For k = 1 to m do 
Sample vm from p (v|hm-1) 
Compute the posterior Q = P (h |vm) 
Sample hm from Q 
end for 
Update weights and bias with contrastive divergence 
W = W +η (h0. v0) – P (hm = 1|vm). vm 
 b = b + η (v0 - vm)  










4.2 Gaussian-Bernoulli RBM 
When the visible units are real values and hidden units are stochastic binary values, RBM 
is called Gaussian-Bernoulli RBM. The energy function of this model becomes 
𝐸(𝐯, 𝐡; θ) =  
1
2𝜎2
∑ (𝑐𝑖 − 𝑣𝑖)







The probability distribution under this model is: 





) , (19) 
𝑝(𝑣𝑖|𝐡) = 𝒩(𝜎𝑖∑𝑊𝑖𝑗ℎ𝑗 + 𝑐𝑖, 𝜎𝑖
2 
𝑖
) , (20) 
where 𝒩(µ, σ2 ) denotes a Gaussian distribution with mean µ and variance σ2 . Each 
visible unit conditioned on hidden states is modeled by a Gaussian distribution, whose 
mean is shifted by the weighted combination of the hidden unit activations. The derivative 
of the log-likelihood with respect to the model parameters takes a very similar form when 
compared to binary RBMs: 
𝜕
𝜕𝑊𝑖𝑗
log 𝑝(𝐯) = 𝔼𝑃𝑑𝑎𝑡𝑎 [
𝑣𝑖
𝜎𝑖




ℎ𝑗] . (21) 
 
4.3 Deep Belief Network 
Deep Belief Networks (DBN) were first proposed in 2006 by Hinton [63]. It is referred 
as a stochastic generative model with several layers of hidden units. DBN can be used as 
supervised or unsupervised algorithm. There are connections between the layers, but not 






DBN is a stacked architecture of RBMs. Deep belief networks similar to Restricted 
Boltzmann Machine, are probabilistic models that use hidden variables to learn features 
from the data. The structure of DBN can be seen in Figure 4.3. Unlike RBMs that learn 
features from input data and is limited in what it can represent, DBNs use multiple layers 




Figure 4.3: Structure of Deep Belief Network 
 
4.3.1 Training 
The training of the DBN has two phases: pre-training and fine-tuning. Hinton introduced 
greedy layer-wise training algorithm in pre-training to initialize parameters before 





DBN are separated pairwise to form two-layered network called RBM. Each RBM is 
trained independently using contrastive divergence, such that the output or hidden layer 
of the lower RBM becomes input or visible layer for the next higher-level RBM and so 
forth such that each stack learns to encode the previous stack. This process can be 
repeated multiple times until all the layers in the stacked architecture are greedily trained 
stack by stack to learn complex probabilistic features. The goal of the pre-training process 
is to perform rough approximations of the model parameters, θ, learned by an RBM that 
define both p(v|h; θ) and the prior distribution over hidden vectors, 𝑝(𝐡|θ). Then the 
probability of generating a visible vector, v, can be derived as: 
𝑝(𝐯) =∑𝑝(𝐡|θ)
𝐡
𝑝(𝐯|𝐡;  θ).    (22) 
After learning parameters, θ,  𝑝(𝐡|θ) can be replaced by learning a better model that 
treats the hidden vectors as the visible layer for another RBM. This replacement improves 
the variational lower bound on log probability of generating the training data under the 
composite model and guarantees the increase in performance.  
 
Unsupervised algorithm employs only pre-training phase, while supervised uses both pre-
training and fine tuning. In case of supervised method, once the network is pre-trained, 
the model looks like feed forward network and can be fine-tuned using a backpropagation 
algorithm such as SGD or CG. This better initialization allows for fast convergence and 
generally requires less refinements of the fine-tuning step.  
In case the input data is real-valued, the first layer is then represented with a Gaussian-









Wl is the weight matrix for layer l 
v is the input training distribution for the network 
bl is the visible bias vector for layer l 
cl is the hidden bias vector for layer l 
R is the no. of layers to train 
for l = 1 to R do 
     Initialize bl = 0, cl = 0, Wl = 0  
 While not stopping criterion do       
    Sample h0 from v 
for i = 1 to l do 
Sample hi from p (hi | hi-1) 
  end for 
RBM Update (hl, Wl, bl, cl) 


















To solve the problem of finding cancer subtypes which can be biologically interpreted, we 
developed two different strategies. In the first approach, we propose a shallow net 
clustering method that use pathway markers which incorporates pathway dataset (i.e. the 
interactions between genes) as prior knowledge and cluster samples into distinct groups. 
In the second approach, we developed a deep net clustering approach that incorporates 
pathway data as hidden layer instead of directly integrating both gene expression and 
pathway data. Adding pathway knowledge to these methods will help in selecting genes 
which are representative for clustering and thus generate clusters that are biologically 
informative. In this chapter, we discuss the first proposed method, its experimental results 
and biological interpretation in detail. We describe latest model in next chapter.     
 
5.1 Model  
A novel pathway-based clustering approach, R-PathCluster was developed to detect cancer 
subtypes. Architecture of R-PathCluster is illustrated in Figure 5.1. R-PathCluster follows 
Gaussian RBM algorithm to obtain subtypes, and thus it has two layers: Input layer and 
Cluster layer. Input layer takes continuous values while the hidden or cluster layer units 
remain binary. The dataset used is pathway markers instead of gene expression data 
directly. Pathway based analysis assures robust and reproducible results whereas gene 






Figure 5.1: Architecture of R-PathCluster 
 
nodes in input layer depends on number of pathway markers and nodes in cluster layer 
depends on number of distinct subtypes we want to identify in the dataset. An outline of 
R-PathCluster framework is illustrated in Figure 5.2.                
 






Pathway markers are generated from gene expression and pathway datasets. Let G = 
{𝒈1, 𝒈2, 𝒈3, … . , 𝒈𝑛 } be the gene expression data of s numbers of samples, i.e., G ∈ ℜs×n. 
From Gene Set Enrichment analysis (GSEA) which is an online pathway database, 
functional annotation of genes can be known. Initially a binary bi-adjacency matrix 
𝑨 ϵ 𝔹𝑝×𝑛 is created based on the biological relationship between p number of pathways 
and n number of genes. If a gene 𝒈𝑖     is present in pathway 𝑝𝑗, then the element 𝑨𝑖𝑗 in 
the bi-adjacency matrix is indicated by one otherwise zero. Gene pathways are constructed 
by matching genes in all the pathways and genes from the gene expression data. Then j-th 
pathway includes a set of gene expressions: 
𝑝𝑗 = {𝒈𝑖|∀𝑖 ∈ ℤ ∶ 𝑨𝑖𝑗 = 1 }.   (23) 
Thus all the pathways in our study will contain genes with gene expression data for all 
samples leading to multi-dimensional dataset. To deal with this problem, Principle 
Component Analysis (PCA) was applied to get linear combinations of gene expression data 
called pathway markers to fit our model. Based on the property of PCA, these pathway 
markers would not only reduce the dimension of gene expression data but keep most of the 
gene information.  
The gene expression of the gene set on the j-th pathway is projected to represent a pathway 
marker of the pathway:  
𝑡𝑗 = 𝑝𝑗𝑎𝑗, (24) 
where 𝑎𝑗 is first principle component obtained by principle component analysis: 
 













Finally, using this equation, pathway markers are obtained for a pathway which represent 
the multiple gene expression data. 
 
 
Figure 5.3: Generation of Pathway Markers using PCA 
 
When R-PathCluster was trained with stochastic gradient and Hinton’s contrastive 
divergence approach similar to RBM, it computes the posterior probability for all samples 
in the cluster layer. The nodes in the cluster layer depends on ‘k’ number of clusters. Then, 
an input data of pathway markers is assigned to a cluster that maximizes the posterior 
probability: 
𝑎𝑟𝑔𝑚𝑎𝑥 𝑝(ℎ𝑗|𝑡𝑗), 𝑗 =  1, … . , 𝑘,   (26) 
where






5.2 Experimental Results 
We conducted experiments with different datasets using Gene expression data and pathway 
data of GBM patients to evaluate our method. Further we evaluated the performance of our 
model with other existing clustering methods such as hierarchical clustering, K-means, and 
general RBM models with different input data.  
 
5.2.1 Datasets 
Gene expression data of all GBM patients and pathway database are used to generate 
pathway markers from these datasets. Each dataset is discussed in detail in next sections. 
 
5.2.1.1 Gene Expression 
Because of wide range of applications of gene expression data in cancer diagnosis, 
prognosis, gene treatments, and other domains [64] [65], gene expression data analysis has 
been gaining lot of attention [66]. With the rapid development of high-throughput 
biotechnologies, it is easy to collect large amount of gene expression data with very low 
costs. Gene expression is the process that measures the gene activity level in the given 
tissue and thus provides information about the complex activities in the corresponding 
cells. This information is usually obtained by measuring the amount of generated 
messenger ribonucleic acid(mRNA) during transcription, a process that measures how 
active or functional the corresponding gene is [67]. As cancer is associated with multiple 
genetic and regulatory aberrations in the cell, these should reflect in the gene expression 





experimental conditions to analyze gene functions, regulatory mechanisms and cancer 
subtypes [68]. Microarrays generally permit to measure the expression levels of tens of 
thousands of genes simultaneously.  
 
In this thesis, we used gene expression matrix of GBM patients obtained from The Cancer 
Genome Atlas (TCGA, available at https://cancergenome.nih.gov). The GBM dataset 
includes gene expression data of 12,042 genes for 522 samples and survival status and 
survival time. Patients who survived more than 24 months are considered as Long Term 
Survival (LTS) patients, and patients who are deceased and survived less than 24 months 
are considered as short term survival (non-LTS) patients. Patients whose survival time is 
less than 24 months and are still living are considered as censored patients. In our dataset, 
there are 99 LTS samples, 365 non-LTS samples and 58 censored samples. The gene 
expression data is normalized between zero and one. 
 
5.2.1.2 Pathway Database  
Standard microarray analysis treats every single gene equally, assuming their expression is 
independent from each other. As mentioned before, cancer is a complex web of interactions 
among multiple genetic and environmental risk factors. As a result, the phenotype or 
disease is not the outcome of single factor but multiple factors that influence each other. 
The assumption of independent gene expression significantly limits its capability of 
providing the underlying relationship among the listed genes or the biological mechanism 
that may cause the phenomenon or phenotype being studied. In order to gain better 





biologically meaningful information with microarray data. Hence pathway databases came 
in to lime light as these have more explanatory power than differently expressed genes and 
also reduce the complexity of analysis [69][70]. 
 
Figure 5.4: The square of Pearson correlations between genes 
 
A biological pathway is defined as a series of molecular actions in a cell that leads to a 
certain product or a change in the state of the cell.  Pathways can also turn genes on and 
off, or spur a cell to move. When something goes wrong in a pathway, the result can be a 
disease such as cancer or diabetes. Identifying the interdependencies and relation between 
the genes, proteins and other molecules and their casual effects in the interrupted 
mechanism can helps in developing personalized medicine for certain diseases. Each 
pathway consists of different set of genes that involved in specific outcome. There are 
many types of biological pathways. Among the most well-known are pathways involved 
in metabolism, gene regulation and signal transmission. For example, Glycogenolysis is a 





species is publicly available from databases in Molecular Signatures Database (MSigDB, 
available at http://software.broadinstitute.org/gsea/msigdb).  
 
For GBM cancer, in our research we considered four pathway databases that include Kyoto 
Encyclopedia of Genes and Genomes (KEGG), Reactome, Pathway Interaction Database 
(PID) and, BioCarta. We showed the square of Pearson correlations between genes of three 
pathways glycolysis/gluconeogenesis, citrate cycle, and pentose phosphate in Figure 5.4, 
in which we noticed that genes with in the same pathways had higher correlations 
comparing to the genes involved in different pathways. In the Figure 5.4, the dotted lines 
in the red indicates the blocks of the correlations between various genes in a pathway. 
 
5.2.1.3 Pathway Markers  
Pathway markers were generated by using functional gene sets obtained from the four 
pathway databases from Molecular Signatures Database (MSigDB). We considered 1,273 
pathway gene sets from overall pathway datasets. Each pathway has different set of genes. 
Gene expression matrix has 12,042 genes data and 522 samples. Among these genes, 
number of genes that have at least one functional annotation of pathways are 6,079.  Then, 
Principle Component analysis (PCA) was applied on the gene expression data of1,273 
functional gene set and by taking first principle component pathway markers are produced. 









5.2.2 Experimental Setting  
We followed a typical design of RBM network for R-PathCluster. Sigmoid function is 
applied for the activation. For the optimal model, we set hyper parameters like learning 
rate as 0.0003, Cluster layer nodes (k), ranges from 2 to 4. Number of input nodes will be 
1,273. We updated the parameters using stochastic gradient descent (SGD) 
 
5.2.3 Results 
The R-PathCluster performance was evaluated by comparing with other clustering methods 
like hierarchical clustering, k-means clustering, and RBM models with different input data. 
In hierarchical clustering and k-means clustering, Ward’s minimum variance method and 
Euclidean distance function are used respectively. 
In order to compare the performance, the following three different types for input data were 
considered:  
a) all gene expression data,  
b) gene expression data of genes that are members of the functional gene sets of 1,273 
pathways,  
c) pathway markers.  
The three types of the input data are annotated by the subscripts ‘GE’, ‘PG’, and ‘PM’ 
respectively. We applied all clustering methods for these three types of input data. For easy 
interpretation we annotated k- meansGE as k-means clustering method with all gene 
expression data, while k- meansPG indicates a k-means clustering that takes only genes of 






In R-PathCluster method we used only Pathway Markers, while in other two RBM models, 
RBMGE and RBMPG 12,042 genes from gene expression data and 6,079 numbers of genes 
from functional gene sets of 1,273 pathways were introduced in the visible layer of these 
RBM models respectively while the hidden layer corresponds to the clustering.  
 
5.2.3.1 Performance Metrics 
The data should be normalized between zero and one for all the models. These clustering 
methods were repeated several times with multiple number of clusters in order to find the 
optimal number of clusters of the GBM samples. We carried out experiments for each 
model with given number of clusters for 10 times and selected the model with highest 
performance as optimal model. We analyzed the clustering performance with the different 
cluster numbers between two and four for all models. For clustering methods, performance 
is evaluated using Silhouette index. Therefore, in this research, we examined the average 
silhouette score for all the models. The silhouette score ranges from negative one to 
positive one, where a higher value represents better clustering. The silhouette index of the 
clustered data shows a degree of purity within a cluster and the quality of separation 
between clusters. Also in order to verify distinct subtype identification we employed 
Kaplan-Meier survival analysis. The survival plot of a clustered dataset demonstrates the 
survival distribution of each subgroup and distinct survival rates in each cluster would 






Further, we computed p-value using log rank statistical test in order to test significance 
between clusters. For more than two clusters, we considered the average p-value of 
pairwise log-rank tests as well as the minimal p-value for the statistical significance 
between clusters. 
 
Experimental results for all methods with different cluster sizes are shown in Table1. We 
trained our model with 65,000 epochs until the model is converged with minimum cost 
score. Figure 5.5 displays learning curve of R-PathCluster for Two clusters. We indicated 
the highest values in the performance measurement and p-value (test of significance) with 
different levels of significance 0.05(*) and 0.01(**) in bold font. According to the results 
in the table, k-meansPM has the highest silhouette score of 0.2847 for 2 clusters, whereas 
our model R-PathCluster showed silhouette score of 0.1895 but interestingly it provides 
lowest p-value of 0.0017 in the Kaplan-Meier survival analysis, while for k-meansPM p-
value is 0.0388. Figure 5.6 illustrates the Kaplan-Meier survival analysis for 2 to 4 clusters 
using R-PathCluster. Also the average survival months difference between the two clusters 
is largest for R-PathCluster with 4.7 survival months while for other methods the difference 
was around 3 months. These results show that R-PathCluster contributes a better solution 








Figure 5.5: Learning curve of R-PathCluster for two clusters 
    
We also conducted experiments for 3 and 4 clusters with all methods but the results are not 
that significant when compared with 2 clusters. This proves that the samples of GBM can 

















Table 1: Comparison of results of all methods using R-PathCluster 
Tumor 
Subtypes 





        2 
k-meansG   17.8, 14.7 0.1049 0.0370* 0.0370* 
k-meansPM   19.0, 16 0.2847 0.0388* 0.0388* 
HierarchicalG   14.4, 17.2 0.1169 0.0713 0.0713 
HierarchicalPM   15.4, 18 0.1637 0.0455* 0.0455* 
RBMG   16.8, 15.7 0.2568 0.5219 0.5219 
RBMPM   19.8, 16.2 0.214 0.1301 0.1301 




        3 
k-meansG   17.2, 20.8, 13.7 0.1051 0.0878 0.0052** 
k-meansPM   17.4, 13.6, 21.7 0.2018 0.0579 0.0023** 
HierarchicalG   14.4, 16.7, 20.9 0.1213 0.0944 0.0225* 
HierarchicalPM   15.4, 19.7, 17.7 0.1556 0.3963 0.0502 
RBMG   22.3, 20.6, 16.3 0.2284 0.2927 0.2128 
RBMPM   16.4, 21.3, 18.1 0.2493 0.7056 0.5644 




        4 
k-meansG   23.1, 13.7, 17.3, 15.7 0.1073 0.2286 0.0011** 
k-meansPM   16.7, 13.3, 21.1, 18.8 0.1674 0.2139 0.0074** 
HierarchicalG   14.4, 16.7, 26.5, 16.3 0.1219 0.2814 0.0037** 
HierarchicalPM   16.8, 13.9, 19.7, 17.7 0.1419 0.3586 0.0186* 
RBMG   21.6, 16.4, 21.8, 17.6 0.2291 0.7142 0.3892 
RBMPM   28.7, 20.1, 29.8, 16.1 0.1864 0.4444 0.1534 
R-PathCluster   
13.1, 13.2, 14.6, 18.1 0.0839 0.4168 0.0054** 














In Figure 5.6, we can interpret when k = 2, the survival probability of the cluster 0 shows 
significantly greater than the cluster 1. 
 
5.2.3.2 Comparison of Age Distributions 
To compare difference of mean ages between clusters we applied one-way ANOVA test. 
One tailed test is preferred to increase detection power. Figure 5.7 denotes boxplot of age 
distributions of clusters when k=2. As the ANOVA test p- value is 2.7e-3 which is less 
than 0.05, we can conclude with 95 % confidence interval that subgroups we identified are 





Figure 5.7: ANOVA comparison of age for k = 2 
 
In Figure 5.7, y-axis represents patient survival months; x- axis represent cluster ids. Start 
edge and end edge of a boxplot shows months range for each cluster and middle line in the 








Although R-PathCluster yield most promising results, we further analyzed its contribution 
in interpreting the identified clusters biologically. In this section, we demonstrate a 
biological mechanism inferred by R-PathCluster by examining the coefficient values. 
First we examined the pathway markers that has the highest coefficient values and top 
five pathways for each cluster are identified and shown in Table 2. From KM survival 
analysis, we identified that cluster 0 represents LTS cluster and cluster 1 represents non-
LTS cluster.  
 
Table 2: Top five pathways for each cluster using R-PathCluster 
Cluster Pathways W in clust 
0 
W in clust 
1 cluster 1 
Genes 
#  
   
   0 
cytochrome P450 0.5469  
 
0.4004 91 
ER-Phagosome pathway 0.5468 0.0890 90 
p53-dependent G1 DNA damage response 0.5440 0.1948 29 
PDGFR-alpha signaling pathway 0.5278 0.2455 14 
nitric oxide signaling pathway 0.4975 0.3631 17 
   
 
   1 
sphingolipid metabolism 0.1502 0.5757 38 
Regulation of RhoA activity 0.2724 0.5575 118 
PPAR 0.2214 0.5247 11 
IL22 soluble receptor signaling pathway 0.2454 0.5072 11 
wnt signaling pathway 0.1938 0.5031 39 
 
According to the weights in the table, the five pathways, cytochrome P450 pathway, ER-





signaling pathway, and nitric oxide signaling pathway belong to the LTS cluster (cluster 
0), while sphingolipid metabolism pathway, Regulation of RhoA activity pathway, 
Peroxisome proliferator-activated receptors alpha (PPARA) pathway, IL22 soluble 
receptor signaling pathway, and wnt signaling pathway belong to the non-LTS cluster 
(cluster 1). Specifically, sphingolipid metabolism pathway produces sphingosine kinase-
1 enzyme which produce sphingosine 1-phosphate (S1P) that activate growth and 
invasiveness of glioma cells. Higher expression levels of the sphingosine kinase-1 
enzyme is correlated with short term survival rate of glioblastoma patients [72]. Over 
expression of p53 gene is reported in LTS glioma patients than non-LTS because of its 
lower proliferation rate compared with typical GBM survivors [73]. High expression of 
Wnt signaling/𝛽-catenin recorded short survival and poor prognosis in GBM patients [74], 












In this chapter we discuss our proposed Sparse PAthway based CLustering (SPACL) model 
to find biologically interpretable cancer subtypes by clustering pathway data. The 
architecture of our model consists of input layer, three hidden layers and final cluster layer. 
The first layer called as input layer that represents the gene expression data. Second layer 
is called pathway specific hidden layer that incorporates pathway data. Two hidden layer 
that represents hierarchical relationship among pathways and first hidden layer and finally 
a cluster layer that corresponds the subtypes of cancer. In this model we also considered 
sparsity between and in the layers which gives us good interpretability for our model. The 
architecture of our model can be seen in Figure 6.1.   
 






6.1.1 Input Layer 
Input layer corresponds to the gene expression of given cancer data. Number of nodes in 
input layer varies with respect to number of genes in the dataset. Each node corresponds to 
one gene feature. Assume that 𝐿 number of genes present in at least one pathway. So the 
nodes in input layer for our model will be 𝐿. 
 
6.1.2 Pathway specific hidden layer 
This layer corresponds to biological pathway dataset. Each node in this layer represents an 
individual pathway. The pathway data is derived from Reactome pathway database. 
Pathway databases has associations between pathways and genes. Each pathway has set of 
genes and each gene can be associated with multiple pathways. The connections between 
input layer and pathway specific hidden layer is interpreted as the biological relationship 
between the genes and pathways. Thus, the pathway specific hidden layer makes it possible 
to interpret the model as pathway based analysis. In order to represent the connections 
between 𝐿 genes in input layer and 𝑃𝑹 pathways in pathway specific hidden layer, binary 
bi-adjacency matrix 𝐀 ϵ  𝔹𝑃
𝑅×𝐿  was created. An element 𝐀𝑖𝑗 is set to one if gene  𝑗 
belongs to pathway 𝑖 , otherwise zero. This bi-adjacency matrix is used to model the 
sparsity between input and pathway specific hidden layer. 
 
6.1.3 Hidden Layer 
The hidden layers in general represents complex nonlinear associations embedded in the 





our proposed SPACL model, hidden layer encodes activation states of combination of 
pathways. Sparsity is applied between the pathway specific hidden layer and hidden layer 
using mask matrix which enables to interpret the relationship. Selection of optimal number 
of hidden layers and number of nodes in the hidden layer is important as it impacts the 
performance of the model. In general, adding more hidden units improves the model 
representational power. However, larger number hidden nodes increase the risk of over 
fitting as the learned features becomes strongly correlated and run time efficiency 
decreases because of too many parameters. 
 
6.1.4 Cluster layer 
This layer encodes posterior probability for each cluster. Number of nodes in this layer 
corresponds to number of clusters. By using argmax function, each sample is assigned to a 
cluster that has highest posterior probability. 
 
6.1.5 Sparsity 
In our model sparsity between layers is regulated by using jointDrop which includes 
dropout and DropConnect. Dropout is generally used to reduce overfitting. The dropout 
module executes the idea of randomly eliminating hidden neurons according to a dropout 
ratio φ and rebuilds a new small sparse network with leftover hidden nodes and all visible 
nodes. When dropout is applied the conditional distributions for input and hidden nodes 
will be: 
 𝑝(ℎ𝑗 = 1|𝐯, 𝑑) = 𝑑𝑘. 𝑠𝑖𝑔 (∑𝑊𝑖𝑗𝑣𝑖 + 𝑏𝑗
𝑖





   
𝑝(𝑣𝑖 = 1|𝐡, 𝑑) = 𝑑𝑘. 𝑠𝑖𝑔 (∑𝑊𝑖𝑗ℎ𝑗 + 𝑐𝑖
𝑗
) ,  (29) 
where d is the binary vector 𝑑 ϵ {0,1}. Each random variable 𝑑𝑘 takes the value 1 with 
dropout ratio φ, independent of others. If 𝑑𝑘  takes the value 1, the hidden unit ℎ𝑗  is 
retained, otherwise it is dropped from the model. 
 
DropConnect introduces dynamic sparsity by dropping connections between hidden layers. 
The sparsity is determined by mask matrix M on the connections between hidden layers 
as: 
𝐡(𝑙+1) = 𝑓((𝑊𝑙⋆𝑴𝑙  )𝐡𝑙 + 𝑏𝑙),  (30) 
  
 
where ⋆  represents element wise multiplication and 𝑓(. )  is non-linear activation 
function. 𝐡𝑙 is the output of the feature vector of layer l, 𝑊𝑙and 𝑏𝑙 are fully connected 
weight matrix and bias of the corresponding layer respectively. The mask matrix 𝐌 is a 
binary matrix encoding the connection information. This matrix 𝐌 is generated with 
respect to a sparsity level (r)which indicates the proportion of weights to be dropped in 
each layer.  In mask matrix, an element 𝐌ij is set to one if the absolute value of the 
corresponding weight 𝑊ij is greater than some threshold Q, an r-th percentile of absolute 
values of weights 𝑊; otherwise element is set be zero. Sparsity level (r) value ranges 
between 0 and 100, where 0 indicates fully connected neural network while 100 is for no 
connections between hidden layers. During training for each layer, the optimal sparsity 
level (r*) is approximated for each iteration. To obtain optimal sparsity, cost function is 





interpolation to the cost scores, the sparsity level that has minimum cost score can be 
selected as optimal sparsity. For this we assume cost function is continuous with respect to 
sparsity. The individual setting of the sparsity on each layer shows different levels of 
biological associations between genes and pathways. 
 
Thus, in our model, we employ two different types of mask matrices. The mask matrix 
𝐌(0) between input layer and pathway specific hidden layer is determined by the binary 
bi adjacency matrix based on relationship between genes and pathway database where as 
for other layers it is determined by sparsity level. Thus, mask matrices are formulated as: 
 
𝐌(𝑙) = {
1|𝑊(𝑙)| ≥ 𝑄(𝑙),   𝑄(𝑙) = 𝑄(𝑙)𝑄100(1−𝑟)%
(𝑙) (|𝑊(𝑙)|),  𝑖𝑓 𝑙 ≠ 0
𝐀,                                         𝑖𝑓 𝑙 = 0 
.        (31)  
 
i.e., 𝑄(𝑙) is 100(1 − 𝑟)% -th left percentile of |𝑊(𝑙)| if  𝑙 ≠ 0.  
 
In addition, in order to reduce overfitting, we also added L2 regularization or weight decay 
that penalizes the quadratic values of weights in to objective function and decrease the 
noise. An additional term is added to the cost function to account for weights that have 
grown larger. So the cost function, 𝐶 becomes: 





𝜆‖W𝑙‖2,  (32) 
where λ is the regularization parameter used to control just how quickly the weights decay. 
Changing the size of λ can shift the priority of the minimization function from the original 





stay small. As is implied by the name of this type of regularization, the modified cost 
function does not take into account the biases.  
 
6.1.6 Training 
The main advantage of our model when compared to other conventional models is 
initializing small sub network instead of whole network which improves performance and 
reduce computational complexity in case of High Dimension Low Sample size (HDLSS) 
data.  
 
When the model is constructed at first we initialize the connections between input layer 
and pathway specific hidden layer with prior biological knowledge of pathways. Binary bi-
adjacency matrix, 𝐀 generated from gene expression and pathway database is used in 
determining the active and inactive connections between input and pathway specific hidden 
layer. Active connection weights and bias are initialized with random values while inactive 
connection weights are set to zero. As our model is based on deep belief network, it follows 
greedy layer wise training algorithm. Hence the first two layers input and pathway specific 
hidden layer forms two layered network called RBM and trained independently using 
contrastive divergence until the model is converged. During training, we applied dropout 
technique so that sub network is selected. Then the output or hidden layer of the this RBM 
becomes input or visible layer and with hidden layer 1 form new RBM and follows same 
training procedure. The sparsity is introduced in the nodes by drop out and in weighted 
connections between layers by mask matrix generated from cubic-spline interpolation to 





finally can cluster the data based on the probability values at cluster layer. Figure 6.2. 
depicts the training of our model. The weighted connections between input layer and 
pathway specific hidden layer are invariant over the entire training and can be seen in 
Figure 6.2A and applying dropout can be seen in Figure 6.2B. Figure 6.2C explains training 




    
Figure 6.2: Training of SPACL 
 
6.2 Experimental Results 
We applied our model on GBM cancer patient’s dataset and compared the performance 
of our model with other clustering methods.  
 
6.2.1 Datasets 
For the pathway based analysis, we used pathways from ‘Reactome’ pathway database 
which include 674 pathways. For input features, we considered only those genes that 





layer will be 4,362 genes, that belongs to at least one pathway and number of nodes in 
pathway specific hidden layer will be 674. Then we constructed mask matrix 𝐌 between 
input layer and pathway specific hidden layer that has dimensions of (4362 x 674). Note 
that data should be normalized to mean of zero and a standard deviation of one. 
 
6.2.2 Experimental setting 
Our model consists of input layer, pathway specific hidden layer, hidden layer and cluster 
layer. Final frame work of our model consists of 4,362 input nodes, 674 pathway nodes, 
400 hidden layer 1 nodes, 100 hidden layer 2 nodes and 2 cluster layer nodes (varies 
depending on cluster size). We conducted the experiment for different cluster numbers 
ranging from two to five. Sigmoid function and mean square error were considered for 
activation and cost function respectively. For optimal model, we empirically determined 
hyper parameters from multiple experiments and set learning rate as 0.5 and λ as 1e-4, 
dropout ratio for all the layers as 0.7.  
 
6.2.3 Results 
We evaluated our model by comparing the performances with other clustering methods 
like hierarchical, k-means, spectral, RBM and DBN models. For all the models, we used 
4,362 genes, that belongs to at least one pathway as input. 
 
Depending on the initial values, the clustering methods may produce different results. 
Since the RBM and DBN models follows the stochastic gradient descent approach, the 









Figure 6.3: Learning curves for all layers 
We repeated the experiment with various number of clusters in order to find the optimal 
number of clusters of GBM samples. In this study, we evaluated the clustering performance 
with the cluster number between two to four by silhouette index and Kaplan-Meier survival 
analysis.  
 
The average silhouette score and p-value of all methods are shown in Table 2. We trained 





in Figure 6.3 for Two clusters. According to the results in the table, our model outperforms 
other models with the highest silhouette score of 0.18658 and lowest p-value of 0.0026 in 
the Kaplan-Meier survival analysis. The Kaplan-Meier survival analysis for 2 to 4 clusters 
using our model is depicted in Figure 6.4. Also we performed ANOVA test to compare the 
age distribution between clusters and that results for two clusters can be seen in Figure 6.5. 
When k = 2, the difference of the average survival months between the two clusters is 
largest (7.49) for our proposed SPACL model while for other methods the difference was 
less than 2 months. From these results it is clearly evident that our model provides a better 
solution for identifying subtypes that consider the survival rates.   
 
We also conducted experiments for three and four clusters with all methods but the results 
are not that significant when compared with two clusters. Figure 6.6 illustrates the 
silhouette plot for 2 to 4 clusters. This proves that the samples of GBM can be clustered 


















Figure 6.5: ANOVA comparison of age for k = 2 
 




Clusters Methods  Silhouette 
Score 
p-value Min(p-values) 
   
 



























     
 
















 RBM 0.00153 0.487635 0.294562 






    
 
















 RBM 0.00896 0.468135 0.293485 




















We analyzed the experimental results biologically which is a noticeable contribution of 
our novel model. We examined the coefficient values between last hidden layer and 
cluster layer. Figure 6.7 depicts the heat map of absolute weight values after sorting, 
where the weighted connections which are dropped are colored in weight. This image 
discloses the distinct patterns of weights for two neurons in cluster layer.  
 
 
Figure 6.7: Weights between the hidden layer and cluster layer 
 
Further, we analyzed the posterior probabilities of output nodes, which are exhibited in 
Figure 6.8. This figure reveals that the samples belong to cluster 0 has higher posterior 
probabilities for output node 0 when compared to node 1 and vice versa for samples 
belong to cluster 1. The top five pathways for each cluster are shown in Table 4. 
Pathways are identified based on the larger weighted connections between hidden layer 
and pathway specific hidden layer. From our model we find the pathways like 
metabolism of proteins, Regulation of kit signaling, p53 dependent G1 dna damage 





(LTS), whereas PI3K AKT activation, signaling by wnt, signaling by constitutively 
active EGFR, signaling to RAS, TGF beta receptor signaling activates SMADS 
pathways involved in cluster 1 (non-LTS). 
 
Figure 6.8: The output node values for two clusters 
 
Table 4: Top five pathways for each cluster using SPACL 
Cluster Pathways Pathway size Genes 
used 
 
   
   0 
Metabolism of proteins 518 335 
Regulation of kit signaling 17 14 
p53 dependent G1 dna damage response 57 51 
signaling to p38 via RIT and RIN 15 13 
Hemostasis 466 397 
   
 
   1 
 
PI3K AKT activation 38 29 
signaling by wnt, ,  65 60 
signaling by constitutively active EGFR, 18 16 
signaling to RAS 27 24 







Figure 6.9: Hierarchical representation of pathways 
 
Biological literature shows that all these pathways are significant in providing 
personalized medicine by targeting these pathways and corresponding genes. Figure 
6.9 illustrates training of our model by activating the pathways and hidden nodes by 
corresponding genes. Metabolism of proteins and KIT signaling pathway activate 
hidden nodes one and three in hidden layer one. Further these two nodes will activate 
hidden node one in hidden layer two and in turn activates the output node 0 in cluster 
layer. This represents that the activation levels of these two pathways will be in 









Cancer is caused by multiple genomic alterations or dysfunction in molecular systems. It 
is a complex and heterogeneous disease with multiple subtypes and lack of knowledge on 
subtypes hinders developing effective targeted therapies and bringing in the personalized 
medicine objective. With the rapid advancement in micro array and next-generation 
sequencing (NGS) technologies, it is possible to analyze a large cohort of patients and 
record patient genomic alterations and expression dysregulations. This accelerates many 
opportunities in redefining cancer subtypes. 
 
The widely adapted approach in finding subtypes is applying unsupervised techniques on 
genomic data of patients. The clusters are deemed interesting if they are found to be 
associated with a clinical variable of interest. In this work, we aim at developing methods 
that can identify cancer subtypes that can be biologically interpreted from high-throughput 
gene expression data. We proposed two different new clustering approaches that 
incorporates the pathway information to detect biologically informative sample subtypes. 
In the first approach, we developed R-PathCluster model in which pathway markers are 
used as input data instead of gene expression data and showed promising clustering 
performance. In the second approach we proposed SPACL model that takes leverage of 
prior biological knowledge of pathway database. We added pathway data as separate layer 
to compute hierarchical complex nonlinear representations between pathway and hidden 





detect any cancer subtypes. Our models R-PathCluster and SPACL showed the significant 
difference in terms of survival rates by Kaplan-Meier survival analysis for two clusters. 
The results for silhouette score, KM analysis, ANOVA test prove that our models 
outperform the other conventional clustering methods. Though both methods can detect 
cancer subtypes, because of deep neural net frame work and sparsity in SPACL model, it 
resolves the challenges faced by HDLSS data and can represents the nonlinear hierarchical 
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